The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

10 articles for BV Joshi


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Structure-activity relationship of (N)-Methanocarba phosphonate analogues of 5'-AMP as cardioprotective agents acting through a cardiac P2X receptor.EBI
National Institutes of Diabetes and Digestive and Kidney Diseases
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Synthesis and P2Y receptor activity of nucleoside 5'-phosphonate derivatives.EBI
Ghent University
Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Synthesis and structure-activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor.EBI
Institute of Science and Technology
P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference.EBI
Niddk
Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.EBI
National Institute of Diabetes and Digestive and Kidney Diseases